Medicare drug plans considerably boosted protection of biosimilar variations of the Humira rheumatoid arthritis drugs this 12 months, however practically all of them did not take steps that may encourage higher use of those different remedies, a brand new authorities watchdog report finds.
The report discovered that 96% of the Half D plans and 88% of the Medicare Benefit drug plans agreed to cowl at the least one of many 10 obtainable copycat medicine on their 2025 formularies. And a few didn’t cowl the brand-name model. This was a giant soar in protection from 2024, when solely 64% of the Half D plans and 52% of the Medicare Benefit drug plans lined at the least one biosimilar model of Humira.
General, 99% of enrollees in Half D Plans and 90% in Medicare Benefit drug plans had entry to at the least one Humira biosimilar in 2025. Nevertheless, some plans are nonetheless limiting entry to the biosimilars this 12 months, which precludes utilization. Particularly, 10% of Medicare Benefit drug plans and 1% of Half D plans cowl solely the brand-name remedy.
This text is unique to STAT+ subscribers
Unlock this text — plus in-depth evaluation, newsletters, premium occasions, and information alerts.
Have already got an account? Log in
To learn the remainder of this story subscribe to STAT+.
